Current Value
$1.931 Year Return
Current Value
$1.931 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
OKLO | 32.91% | $5.21B | +288.07% | 0.00% |
CLFD | 30.74% | $538.99M | +5.27% | 0.00% |
BIP | 27.11% | $14.99B | +6.59% | 5.08% |
EYPT | 27.04% | $393.60M | -54.31% | 0.00% |
NNOX | 26.96% | $347.50M | -44.56% | 0.00% |
FOLD | 26.57% | $1.83B | -37.37% | 0.00% |
AB | 26.28% | $4.48B | +19.08% | 8.24% |
CMPS | 26.20% | $366.75M | -50.56% | 0.00% |
NNDM | 26.10% | $342.01M | -41.57% | 0.00% |
OCUL | 25.94% | $1.14B | +14.35% | 0.00% |
IRDM | 25.85% | $2.77B | -15.74% | 2.18% |
TLPH | 25.79% | $10.05M | -57.39% | 0.00% |
KRRO | 25.60% | $135.97M | -71.75% | 0.00% |
CALX | 25.53% | $2.93B | +45.08% | 0.00% |
AUTL | 25.22% | $343.32M | -68.30% | 0.00% |
CMBM | 25.04% | $14.07M | -86.17% | 0.00% |
MGTX | 24.66% | $405.04M | -11.27% | 0.00% |
SKLZ | 24.53% | $114.70M | +0.78% | 0.00% |
CSCO | 24.49% | $255.64B | +32.93% | 2.54% |
TYRA | 24.47% | $523.47M | -48.38% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CF | -<0.01% | $13.97B | +11.52% | 2.32% |
ARHS | 0.01% | $1.18B | -48.96% | 0.00% |
SW | -0.01% | $24.34B | +0.89% | 2.25% |
YRD | -0.02% | $511.78M | +17.66% | 7.06% |
BDX | 0.02% | $49.37B | -27.20% | 2.32% |
COCO | 0.02% | $1.96B | +31.80% | 0.00% |
FE | 0.03% | $24.49B | +5.52% | 4.06% |
BLDR | 0.03% | $13.04B | -28.68% | 0.00% |
MODV | -0.03% | $12.77M | -96.80% | 0.00% |
MSEX | 0.03% | $1.02B | -1.01% | 2.34% |
WST | 0.04% | $15.14B | -40.50% | 0.39% |
AXGN | -0.05% | $536.51M | +97.32% | 0.00% |
MDLZ | 0.05% | $84.34B | -9.43% | 2.85% |
SD | -0.05% | $377.51M | -23.32% | 4.28% |
NHI | -0.06% | $3.48B | +11.97% | 4.82% |
LTM | 0.07% | $11.01B | -96.75% | 2.75% |
CTRA | 0.07% | $18.84B | -11.85% | 4.32% |
AES | -0.07% | $8.83B | -41.54% | 5.63% |
LYB | 0.07% | $18.78B | -41.54% | 9.22% |
BCRX | -0.07% | $2.14B | +57.81% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IBDQ | -0.07% | $3.08B | 0.1% |
XLE | -0.09% | $27.81B | 0.09% |
IHF | -0.09% | $597.70M | 0.4% |
SMMU | -0.10% | $822.53M | 0.35% |
XOP | -0.12% | $2.09B | 0.35% |
KRBN | 0.29% | $160.09M | 0.85% |
PWZ | 0.30% | $671.52M | 0.28% |
FXG | -0.30% | $316.41M | 0.63% |
FTXN | -0.31% | $134.61M | 0.6% |
FCG | 0.31% | $348.88M | 0.6% |
CGSM | 0.34% | $658.61M | 0.25% |
BSMW | -0.43% | $102.62M | 0.18% |
IYE | 0.45% | $1.19B | 0.39% |
FXN | 0.45% | $296.44M | 0.62% |
TPMN | 0.51% | $31.54M | 0.65% |
KCCA | 0.55% | $97.18M | 0.87% |
SHM | 0.56% | $3.37B | 0.2% |
IEO | -0.63% | $503.02M | 0.4% |
MUST | -0.64% | $403.58M | 0.23% |
RSPG | 0.65% | $455.67M | 0.4% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
NUKZ | 31.27% | $218.87M | 0.85% |
URA | 26.72% | $2.88B | 0.69% |
FFTY | 25.93% | $65.22M | 0.8% |
PFFR | 24.59% | $91.48M | 0.45% |
IWC | 24.56% | $766.88M | 0.6% |
IWMY | 23.48% | $109.62M | 1.02% |
PRNT | 23.36% | $79.83M | 0.66% |
ITEQ | 23.34% | $90.24M | 0.75% |
BLCN | 23.18% | $47.77M | 0.68% |
FTLS | 22.86% | $1.98B | 1.38% |
ARKX | 22.70% | $287.52M | 0.75% |
ARTY | 22.39% | $905.69M | 0.47% |
XSW | 22.27% | $490.45M | 0.35% |
IMOM | 22.18% | $90.83M | 0.39% |
SIXG | 22.16% | $567.70M | 0.3% |
PSP | 22.13% | $257.96M | 1.79% |
IHAK | 21.97% | $921.20M | 0.47% |
IZRL | 21.96% | $105.19M | 0.49% |
CIBR | 21.93% | $9.10B | 0.59% |
ARKG | 21.89% | $944.78M | 0.75% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
STNG | -16.45% | $2.13B | -48.56% | 3.81% |
FI | -14.16% | $88.23B | +4.12% | 0.00% |
CL | -12.98% | $72.64B | -5.18% | 2.25% |
CNC | -12.32% | $29.89B | -22.14% | 0.00% |
PPC | -11.94% | $11.21B | +41.54% | 0.00% |
TRMD | -11.58% | $1.74B | -53.07% | 28.35% |
MOH | -11.48% | $17.02B | -8.99% | 0.00% |
GOGL | -11.11% | $1.59B | -47.16% | 12.97% |
GIS | -10.22% | $29.79B | -23.81% | 4.42% |
PEP | -10.05% | $180.30B | -28.19% | 4.14% |
MOMO | -9.74% | $768.25M | +8.00% | 0.00% |
HSY | -9.53% | $33.16B | -21.37% | 3.44% |
BG | -9.25% | $10.76B | -23.23% | 3.40% |
ASC | -9.11% | $402.99M | -56.03% | 9.46% |
FRO | -8.78% | $4.02B | -33.86% | 9.65% |
ARCO | -8.66% | $1.56B | -29.25% | 3.25% |
JJSF | -8.49% | $2.26B | -29.86% | 2.67% |
HPK | -8.43% | $1.25B | -31.68% | 1.63% |
NFE | -8.07% | $688.19M | -90.38% | 3.91% |
SHLS | -8.06% | $765.66M | -33.04% | 0.00% |
Yahoo
According to the company, the trial’s open-label data is anticipated in the latter half of this year.
Yahoo
ACESOT-1051 Trial Expanded to Include HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) Patients, Targeting Populations Most Likely to Benefit for WEEI InhibitionDOYLESTOWN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today announced that a patient with HPV+ head an
Yahoo
Aprea Therapeutics ( NASDAQ:APRE ) Full Year 2024 Results Key Financial Results Net loss: US$13.0m (loss narrowed by...
Yahoo
ACESOT-1051 trial evaluating WEE1 kinase inhibitor APR-1051 now enrolling patients in Cohort 5; open label safety and efficacy data expected H2 2025 Twice daily (BID) dosing regimen in ongoing ABOYA-119 trial expected to maximize clinical benefit of ATR inhibitor ATRN-119; plan to complete dose escalation H2 2025 $22.8 million in cash and cash equivalents as of December 31, 2024 DOYLESTOWN, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”
Yahoo
DOYLESTOWN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, announced today that it has entered into a Material Transfer Agreement (MTA) with MD Anderson Cancer Center. Under the agreement, Aprea will supply its proprietary WEE1 kinase inhibitor, APR-1051, to support pre
Yahoo
Aprea Therapeutics (APRE) provided an update on its existing patent portfolio. Aprea’s ATR inhibitor program is protected by a strong patent estate, including four granted U.S. patents, one pending U.S. application, and one pending provisional application. There are 19 granted non-U.S. patents and 16 pending non-U.S. patent applications. The granted patents will expire 2035-2037 and the pending applications, if granted, could extend exclusivity into 2044. Additional regulatory exclusivities up t
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -13.70% | $361.41M | 1.43% |
DBE | -13.36% | $48.48M | 0.77% |
VIXY | -13.33% | $109.64M | 0.85% |
TAIL | -12.12% | $140.49M | 0.59% |
USDU | -12.01% | $173.44M | 0.5% |
USL | -10.96% | $41.76M | 0.85% |
BNO | -10.74% | $86.13M | 1% |
USO | -10.53% | $956.18M | 0.6% |
OILK | -10.51% | $63.21M | 0.69% |
CCOR | -9.79% | $59.79M | 1.18% |
PDBC | -9.58% | $4.43B | 0.59% |
COMT | -9.55% | $606.15M | 0.48% |
DBO | -9.40% | $182.54M | 0.77% |
UUP | -9.25% | $292.27M | 0.77% |
DBC | -8.71% | $1.17B | 0.87% |
UGA | -8.61% | $73.47M | 0.97% |
SOYB | -8.48% | $25.54M | 0.22% |
GSG | -8.41% | $917.54M | 0.75% |
CANE | -6.65% | $10.71M | 0.29% |
SGOV | -6.57% | $45.91B | 0.09% |